Initial Public Offering
Baird served as co-manager on this transaction.
AboutAuspex Pharmaceuticals, Inc. (“Auspex” or the “Company”) (NASDAQ-GS: ASPX) recently completed an initial public offering of 8,050,000 shares of common stock at a price of $12.00 per share, generating gross proceeds of $96.6 million. The Company intends to use the net proceeds from the offering primarily for the clinical development and commercialization of SD-809, as well as for general corporate purposes.
Auspex is a biopharmaceutical company focused on the development and commercialization of medicines for the treatment of orphan diseases. Auspex's pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea associated with Huntington's disease, tardive dyskinesia and Tourette syndrome, as well as other orphan indications. Auspex's product candidate, SD-809, is in a Phase 3 registration clinical trial for the treatment of chorea (abnormal involuntary movements) associated with Huntington's disease. Auspex has employed its deuterium chemistry approach to optimize other deuterium-containing compounds in its portfolio that are at various stages of development. The Company is headquartered in San Diego, California.
For additional information about this transaction, please contact:
- February 2014
- Auspex Pharmaceuticals, Inc.
- Target Location
- North America